Regenxbio Inc

NASDAQ:RGNX  
35.15
-0.03 (-0.08%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.49B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$18.59 Million
Adjusted EPS-$1.24
See more estimates
10-Day MAN/A
50-Day MAN/A
200-Day MAN/A
See more pivots

REGENXBIO, Inc. Stock, NASDAQ:RGNX

9600 Blackwell Road, Suite 210, Rockville, Maryland 20850
United States of America
Phone: +1.240.552.8181
Number of Employees: 257

Description

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.